NP47825 Multiple Sclerosis Medicines

A Contract Award Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)

Source
Find a Tender
Type
Framework (Goods)
Duration
not specified
Value
£602K-£48M
Sector
HEALTH
Published
02 May 2025
Delivery
not specified
Deadline
n/a

Concepts

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Geochart for 1 buyers and 9 suppliers

1 buyer

8 suppliers

Description

Supply of multiple sclerosis medicines to NHS Scotland.

Lot Division

1 Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab

Supply of glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per line to six (6) Framework Participants. Full details of Goods and volumes can be found within the ITT (Invitation to Tender) documents.
2 Fingolimod capsules, teriflunomide tablets, and dimethyl fumarate capsules

Supply of fingolimod capsules, teriflunomide tablets, and dimethyl fumarate capsules to NHS Scotland. The Authority has award this Lot as a single supplier Framework Agreement per product line to three (3) Framework Participants. Full details of Goods and volumes can be found within the ITT documents.

Award Detail

1 Sandoz (Camberley)
  • Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab
  • Reference: 018635-2025-1
  • Value: £47,968,904 [share]
  • Awarded to group of suppliers.
2 Merck Serono (Middlesex)
  • Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab
  • Reference: 018635-2025-1
  • Value: £47,968,904 [share]
  • Awarded to group of suppliers.
3 Orifarm (Hemel Hempstead)
  • Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab
  • Reference: 018635-2025-1
  • Value: £47,968,904 [share]
  • Awarded to group of suppliers.
4 Viatris UK Healthcare (Hatfield)
  • Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab
  • Reference: 018635-2025-1
  • Value: £47,968,904 [share]
  • Awarded to group of suppliers.
5 Biogen Idec (Maidenhead)
  • Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab
  • Reference: 018635-2025-1
  • Value: £47,968,904 [share]
  • Awarded to group of suppliers.
6 Teva (Castleford)
  • Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab
  • Reference: 018635-2025-1
  • Value: £47,968,904 [share]
  • Awarded to group of suppliers.
7 Stada UK Thornton & Ross (Huddersfield)
  • Fingolimod capsules, teriflunomide tablets, and dimethyl fumarate capsules
  • Reference: 018635-2025-2
  • Value: £602,376 [share]
  • Awarded to group of suppliers.
8 Ranbaxy (London)
  • Fingolimod capsules, teriflunomide tablets, and dimethyl fumarate capsules
  • Reference: 018635-2025-2
  • Value: £602,376 [share]
  • Awarded to group of suppliers.
9 Teva (Castleford)
  • Fingolimod capsules, teriflunomide tablets, and dimethyl fumarate capsules
  • Reference: 018635-2025-2
  • Value: £602,376 [share]
  • Awarded to group of suppliers.

Award Criteria

Technical (Supply Chain) 5
price 95

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated values referred to in Section II.1.7 and Section V.2.4 and within all Lots cover the twenty-seven (27) month contract duration and the twenty-one (21) month extension period of the Framework Agreement. (SC Ref:797683)

Reference

Domains